Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study
Cancer · 2023
DOI: 10.1002/cncr.34783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Gypsyamber D'Souza und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Oropharyngeal Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: World Health Organization, NIDCR NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Background
Human papillomavirus (HPV)‐related oropharyngeal cancer screening is being explored in research studies, but strategies to identify an appropriate population are not established. The authors evaluated whether a screening population could be enriched for participants with oncogenic HPV biomarkers using risk factors for oral HPV.
Methods
Participants were enrolled at Johns Hopkins Hospitals and Mount Sinai Icahn School of Medicine. Eligible participants were either men aged 30 years or older who had two or more lifetime oral sex partners and a personal history of anogenital dysplasia/cancer or partners of patients who had HPV‐related cancer. Oral rinse and serum samples were tested for oncogenic HPV DNA, RNA, and E6 or E7 antibodies, respectively. Participants with any biomarker were considered at‐risk .
Results
Of 1108 individuals, 7.3% had any oncogenic oral HPV DNA, and 22.9% had serum antibodies for oncogenic HPV E6 or E7. Seventeen participants (1.5%) had both oral and blood biomarkers. HPV type 16 (HPV16) biomarkers were rarer, detected in 3.7% of participants, including 20 with oral HPV16 DNA and 22 with HPV16 E6 serum antibodies ( n = 1 had both). In adjusted analysis, living with HIV (adjusted odds ratio, 2.65; 95% CI, 1.60–4.40) and older age (66–86 vs. 24–45 years; adjusted odds ratio, 1.70; 95% CI, 1.07–2.70) were significant predictors of being at risk. Compared with the general population, the prevalence of oral HPV16 (1.8% vs. 0.9%), any oncogenic oral HPV DNA (7.3% vs. 3.5%), and HPV16 E6 antibodies (2.2% vs. 0.3%) was significantly elevated.
Conclusions
Enrichment by the eligibility criteria successfully identified a population with higher biomarker prevalence, including HPV16 biomarkers, that may be considered for screening trials. Most in this group are still expected to have a low risk of oropharyngeal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medicine, Baltimore, Maryland, USA.
- Division of Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
- Viroclinics-DDL Diagnostic Laboratory, Rijswijk, Netherlands.
- Department of Otolaryngology-Head and Neck Surgery, Northwell Health, New York, New York, USA.
- Genomic Epidemiology Branch, International Agency for Research on Cancer, Lyon, France.
ORCID-Profile: Sakshi R Tewari, Carole Fakhry
Förderung
- World Health Organization
- NIDCR NIH HHS
- NCI NIH HHS
- National Institute of Dental and Craniofacial Research
- National Cancer Institute
Zitieren
APA
D'Souza, G., Tewari, S. R., Troy, T., Waterboer, T., Struijk, L., Castillo, R., Wright, H., Shen, M., Miles, B., Johansson, M., Robbins, H. A., & Fakhry, C. (2023). Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. https://doi.org/10.1002/cncr.34783
Vancouver
D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, et al. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023. doi:10.1002/cncr.34783
BibTeX
@article{DSouza2023,
author = {D'Souza, Gypsyamber and Tewari, Sakshi R and Troy, Tanya and Waterboer, Tim and Struijk, Linda and Castillo, Rachel and Wright, Hannah and Shen, Michael and Miles, Brett and Johansson, Mattias and Robbins, Hilary A and Fakhry, Carole},
title = {Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34783}
}
EUVIMED